A Phase 2 interventional study of TARA-002 in Lymphatic Malformation, sponsored by Protara Therapeutics. Recruiting at 11 sites in United States. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Protara Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Lymphatic Abnormalities with a site in United States — 7 open to participants now, 8 under way, 3 of them phase 3. Lymphatic Abnormalities · United States.
Among the 19 studies in Lymphatic Abnormalities with a site in United States, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 2, and was the 14th registered.
42 studies on the registry are indexed under Lymphatic Abnormalities; 17 are open to participants now.
Browse Lymphatic Abnormalities studies →7 of the 19 studies in Lymphatic Abnormalities with a site in United States are open now. Recruiting first, the newest first:
Kaken Pharmaceutical · Sites in United States, Korea, Republic of, Taiwan
Ages 2+
Relay Therapeutics, Inc. · Sites in United States, Australia, Belgium and 7 more countries
Ages 2+
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 0–100
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–100 yrs · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 2+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Lymphatic Abnormalities studies recruiting now, 6 (43%) set no upper age limit and 5 (36%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.
This study: 6 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4
First in 2000; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is below the median of 46 across 28 interventional studies indexed under Lymphatic Abnormalities.
Median enrollment 31 across the 16 interventional studies, 1,000 across the 3 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
Protara Therapeutics is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Protara Therapeutics has 1 study filed under Lymphatic Abnormalities — fewer than ten, so there is no comparison to draw.
1 of the studies in Lymphatic Abnormalities with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05871970Protara TherapeuticsSafety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Lymphatic Abnormalities with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For more information on eligibility criteria, please contact the sponsor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TARA-002 is a lyophilized biological preparation for injection containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
Biological: TARA-002
Drug pages: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002
All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
Proportion of participants with clinical success after one treatment cycle of TARA-002
Time frame: 8 weeks after the last injection
Safety: Percentage of participants with solicited local site and systemic reactions
Time frame: 14 days (2 weeks) after each injection
Safety: Percentage of participants with unsolicited adverse events (AEs)
Time frame: Through study completion (approximately 32 weeks after last injection)
Safety: Percentage of participants with SAEs, AEs of special interest, AEs leading to premature discontinuation of study intervention, AEs leading to withdrawal from study, AEs with an outcome of death, and MAAEs
Time frame: Through study completion (approximately 32 weeks after last injection)
Durable Response: Proportion of participants with clinical success after one treatment cycle of TARA-002 assessed at 8 weeks after the last injection and maintained clinical success at 32 weeks after the last injection
Time frame: 32 weeks after the last injection
Clinical Success by LM Type: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002
Time frame: 8 weeks after the last injection
Investigator Assessment: Proportion of participants who demonstrate clinical improvement, as assessed by the Investigator, after one treatment cycle of TARA-002 compared to baseline
Time frame: 8 weeks after last injection and 32 weeks after last injection
Quality of Life: Change in Quality-of-Life assessment based on Pediatric Quality of Life Inventory (PedsQL) and Visual Analog Scale (VAS) for Pain after one treatment cycle of TARA-002
Time frame: 8 weeks after last injection and 32 weeks after last injection
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002
Protara Therapeutics